Article Text

other Versions

PDF
Mavacoxib and meloxicam for canine osteoarthritis: a randomised clinical comparator trial
  1. M. B. Walton, BVSc CertSAS MRCVS1,
  2. E. Cowderoy, VN BSc (Hons), PgD, Vet Physio1,
  3. B. Wustefeld-Janssens, BSc (Agric), BVSc (Hons), MRCVS1,
  4. D. Lascelles, BSc, BVSc, PhD, DSAS(ST), DipECVS, DipACVS, MRCVS 2 and
  5. J. Innes, BVSc, PhD, CertVR, DSAS(Orth), MRCVS1
  1. 1Musculoskeletal Biology and Small Animal Teaching Hospital, University of Liverpool, Neston, Cheshire, UK
  2. 2College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA;
  1. E-mail for correspondence: benwalton{at}live.co.uk

Abstract

NSAIDs are the cornerstone of medical management of canine osteoarthritis (OA). Meloxicam is a daily-administered NSAID widely available in a liquid formulation and manufacturer's summary of product characteristics (SPC) advise that it is given at the lowest effective dose. Mavacoxib is a long-acting NSAID given as a monthly tablet. This study compares these drugs in the management of canine OA. In all, 111 dogs with OA of the elbow, hip or stifle were randomly assigned to receive one of these NSAIDs for a 12-week period, and to administer them as per the manufacturer's SPC. Outcomes, including ground reaction forces and three validated clinical metrology instruments, were measured at baseline, 6 and 12 weeks. Improvements were seen in all outcome measures for both groups to a similar degree, and adverse events occurred at a similar rate. There were significant improvements in outcome measures from week 6 to week 12, as well as from baseline. Long-term meloxicam dose was more important than recent dose. Clinical efficacy and adverse event rates are similar for meloxicam and mavacoxib when administered as per their UK SPC. This is relevant information for veterinary surgeons when prescribing NSAID treatment for canine OA.

  • Accepted April 29, 2014.

Statistics from Altmetric.com

  • Accepted April 29, 2014.
View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.